Allarity Therapeutics (NASDAQ:ALLR) Issues Earnings Results

Allarity Therapeutics (NASDAQ:ALLR) released its earnings results on Friday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.18), FiscalAI reports. The business had revenue of $0.01 million during the quarter. Allarity Therapeutics updated its FY 2026 guidance to -0.760–0.730 EPS and its Q4 2026 guidance to 0.010-0.040 EPS.

Allarity Therapeutics Stock Up 4.4%

Allarity Therapeutics stock traded up $0.04 during trading hours on Friday, hitting $0.95. The stock had a trading volume of 279,178 shares, compared to its average volume of 151,355. The company has a 50-day moving average of $1.02 and a two-hundred day moving average of $1.21. Allarity Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $1.84. The company has a market cap of $15.17 million, a PE ratio of -1.22 and a beta of 0.57.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Allarity Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $10.25.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.